Recently, plasma AD biomarkers, such as phosphorylated-tau (p-tau), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), have been developed to reflect core AD pathology, neuroinflammation, and neurodegeneration, respectively17. This evidence concerns the gene MAPT and Alzheimer disease.